Table 2.
All subjects | Increase | Decrease |
---|---|---|
P ≤ 0·01 | CD3–CD16+CD56+ | CD3+ |
CD4+CD294+ (Th2) | CD3+CD4+ | |
CD14+CD11c– | CD3+CD8+ | |
CD3+CD62L+ | ||
0·01 < P < 0·05 | CD14+CD11c+ | CD4+TIM3+: CD4+294+(Th1 : Th2) |
DR+CD123+ (DC2) | ||
Females | ||
P ≤ 0·01 | CD4+CD294+ (Th2) | CD3+ |
CD14+CD11c– | CD3+CD62L+ | |
0·01 < P < 0·05 | CD3+4+ | |
Males | ||
P ≤ 0·01 | CD4+CD294+ (Th2) | CD3+ |
CD3+CD4+ | ||
CD3+CD8+ | ||
CD3+CD62L+ | ||
0·01 < P < 0·05 | CD3–CD16+CD56+ | CD4+TIM3+ : CD4+294+(Th1 : Th2) |
DR+CD123+ (DC2) |
The significant differences and trends among all subjects and both sexes are displayed.